Literature DB >> 1008993

Selective promoting activity of phorbol myristate acetate in experimental skin carcinogenesis.

R A Bhisey, S M Sirsat.   

Abstract

Experiments were undertaken to study the effect of promotion treatment on epidermal tumour induction pattern in precancerous mouse skin. Swiss albino mice were given a single s.c. injection of 0-5 mg 20-methylcholanthrene in the right scapular region. Six weeks later, 1-83 nmol of phorbol myristate acetate (PMA) was applied biweekly on the reactive skin. Histopathology of the induced tumours showed early appearance of squamous cell carcinomas and rhabdomyosarcomas. Fibrosarcoma, the most common tumour type induced on MCA injection alone, was absent. Trichoepithelioma, a benign tumour, was induced in PMA-treated mice. This gives new evidence of the selective action of PMA, enhancing the induction of epithelial and muscle tumours, with concurrent inhibition of fibroblastic tumours.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1008993      PMCID: PMC2025219          DOI: 10.1038/bjc.1976.229

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  A speculative review; the probable nature of promoting action and its significance in the understanding of the mechanism of carcinogenesis.

Authors:  I BERENBLUM
Journal:  Cancer Res       Date:  1954-08       Impact factor: 12.701

2.  Ultrastructural, histological, and biochemical alterations produced by 12-O-tetradecanoyl-phorbol-13-acetate on mouse epidermis and their relevance to skin tumor promotion.

Authors:  A N Raick
Journal:  Cancer Res       Date:  1973-02       Impact factor: 12.701

Review 3.  Tumor-promoting agents in two-stage carcinogenesis.

Authors:  B L Van Duuren
Journal:  Prog Exp Tumor Res       Date:  1969

4.  Dose-response studies with a pure tumor-promoting agent, phorbol myristate acetate.

Authors:  B L Van Duuren; A Sivak; A Segal; I Seidman; C Katz
Journal:  Cancer Res       Date:  1973-09       Impact factor: 12.701

5.  Early effects of 12-O-tetradecanoyl-phorbol-13-acetate on the incorporation of tritiated precursor into DNA and the thickness of the interfollicular epidermis, and their relation to tumor promotion in mouse skin.

Authors:  A N Raick; K Thumm; B R Chivers
Journal:  Cancer Res       Date:  1972-07       Impact factor: 12.701

6.  Tumor-promoting activity of phorbol and four diesters of phorbol in mouse skin.

Authors:  W M Baird; R K Boutwell
Journal:  Cancer Res       Date:  1971-08       Impact factor: 12.701

7.  Studies on the mechanism of skin tumor promotion.

Authors:  H Hennings; R K Boutwell
Journal:  Cancer Res       Date:  1970-02       Impact factor: 12.701

8.  Cocarcinogenic principles from the seed oil of Croton tiglium and from other Euphorbiaceae.

Authors:  E Hecker
Journal:  Cancer Res       Date:  1968-11       Impact factor: 12.701

9.  The latent period of co-carcinogenesis.

Authors:  M H SALAMAN
Journal:  Br J Cancer       Date:  1952-06       Impact factor: 7.640

10.  Methylcholanthrene carcinogens in the Swiss albino mouse in relation to differential oncogenesis of skin tumours.

Authors:  R A Bhisey; S M Sirsat
Journal:  Br J Cancer       Date:  1966-06       Impact factor: 7.640

  10 in total
  3 in total

1.  Effect of the active tumor promoter, 12-O-tetradecanoylphorbol-13-acetate on hair follicular growth and development of hair anlage tumors in the mouse skin: a comparison with human adnexal lesions.

Authors:  R A Bhisey; B Iyengar; S M Sirsat
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

2.  12-0-Tetradecanoylphorbol-13-acetate-induced amplification of mesenchymal tumorigenesis in the mouse skin.

Authors:  R A Bhisey; A G Ramchandani; B Iyengar; A Borges; S M Sirsat
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

3.  Differential effects of phorbol ester tumor promoters on 3-methylcholanthrene-induced epithelial and mesenchymal skin tumorigenesis.

Authors:  R A Bhisey; A G Ramchandani; P L Veturkar; A M Borges; P N Notani; S M Sirsat
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.